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Summary Analysis of bioactive substances produced by cancer cells is one approach to understanding the
biological features of human cancer. One of these bioactive substances is endothelin (ET)-1, a peptide with
potent vasoconstrictive activity produced by vascular endothelial cells. We have previously reported the
production of ET-1 by several types of human cancer, especially pancreatic cancer cells. To elucidate whether
these cancer cells might share biological characteristics with vascular endothelial cells, we investigated the
production of three ET isoforms in pancreatic cancer cells, using a specific radioimmunoassay. Further, we
also investigated whether these cells produce thrombomodulin (TM), another product of endothelial cells
functioning as a modulator of procoagulant activity. ET-1 was detected in 11 of 12 pancreatic cancer cell lines
(92%) while ET-2 and ET-3 were detectable in only one cell line. Gel filtration analysis confirmed the presence
of ET-1. Moreover, TM was detected in the cell lysates of 11 of the 12 cell lines (92%) and it was released into
the culture medium in the majority (58%) of these cell lines. TM mRNA was also detected in these cells. In
addition, TM was demonstrated immunocytochemically along the cell surface. These results suggest that
pancreatic cancer cells share two characteristics with endothelial cells: the production of ET-1 and TM.
Neoplastic cells frequently produce bioactive substances, such
as hormones, cytokines and growth factors (Imanishi et al.,
1989; Mori et al., 1991; Odell & Appleton, 1992). These
products have the potential to induce responses in remote
target organs, normal tissues surrounding the cancer cells or
the neoplastic cells themselves; these mechanisms of action
are designated as endocrine, paracrine and autocrine respec-
tively. One of these bioactive substances is endothelin (ET)-1,
a peptide with potent vasoconstrictive activity produced by
vascular endothelial cells (Yanagisawa et al., 1988). We have
previously reported the production of ET-1 by several types
of human malignant cells, and raised the possibility that
ET-1 produced by cancer cells stimulates cellular growth of
stromal cells surrounding cancer cells in a paracrine fashion
(Kusuhara et al., 1990). This observation has been confirmed
by other researchers (Schrey et al., 1992; Yamashita et al.,
1992).
The mechanism responsible for the ET-1 production by
cancer cells is presently unknown. We have speculated that
cancer cells producing ET-1 share biological characteristics
with vascular endothelial cells. The present study was under-
taken to explore this possibility. We focused on pancreatic
cancer cells; among various types of malignant cells, pan-
creatic cancer cells produced ET-1 at the highest frequencies
and largest quantities in a relatively small-scale study con-
ducted previously (Kusuhara et al., 1990). To confirm this
first, we prepared 12 human pancreatic cancer cell lines. We
investigated the production of three ET isoforms (Inoue et
al., 1989), ET-1, ET-2 and ET-3, to determine whether the
patterns of expression of ET isoforms were similar to that of
endothelial cells. Furthermore, we examined whether these
cells produced thrombomodulin (TM), which is a modulator
of the coagulation cascade and is predominantly produced in
endothelial cells (Esmon et al., 1982; Maruyama et al.,
1985).
Materials and methods
Materials
Synthetic human ET-1, ET-2 and ET-3 were purchased from
the Peptide Institute (Osaka, Japan); porcine thyroglobulin
from Sigma (St Louis, MO, USA); bovine serum albumin
(BSA, Cohn fraction V) from Daiichi Pure Chemicals
(Osaka); octadecylsilylsilica (ODS) cartridge (Sep-Pak C,8)
from Waters (Milford, MA); Sephadex G-50 superfine from
Pharmacia (Uppsala, Sweden); ['25I]sodium iodide from New
England Nuclear (Boston, MA, USA); ['25I]ET-1, ['25I]ET-2
and [125I]ET-3 with specific activity of 74TBqmmol-' from
Amersham International (Amersham, Bucks, UK); bio-
tinylated anti-mouse IgG and avidin-biotinylated
horseradish peroxidase complex from Vector Laboratories
(Burlingame, CA, USA); and Lab-Tek chamber slides from
Nunc (Naperville, IL, USA).
Cell culture
Sixteen human malignant cell lines were examined. These
were 12 pancreatic cancer cell lines (ASPC-1, BxPC-3, FA-6,
MIAPaCa-2, PANC-1, PSN-1, KP1N, KP2, KP3, H48N,
CAPAN-1 and CAPAN-2), a gastric cancer cell line (MKN-
28), a lung cancer cell line (A-549), a melanoma cell line
(SEKI) and an acute promyelocytic leukaemia cell line
(HL-60). Of these, PSN-1 and SEKI were established at the
National Cancer Center Research Institute (Tokyo, Japan)
(Shimoyama, 1975; Yamada et al., 1986). FA-6 was a gift
from N. Nagata (National Defense Medical College,
Saitama, Japan) (Nagata et al., 1989). KP1N, KP2, KP3,
H48N were established by A. Kono and colleagues (National
Kyushu Cancer Center, Fukuoka, Japan) (Ikeda et al., 1990).
MKN-28 was kindly provided by H. Watanabe (Niigata
University School of Medicine, Niigata, Japan) (Motoyama
et al., 1986). The other cell lines were purchased from the
American Type Culture Collection (Rockville, MD, USA).
As for the pancreatic cancer cell lines, the histopathology of
the original tumours is given in Tables I and II. Normal
human umbilical vein endothelial cells (HUVECs) were pur-
chased from Kurabo Industries (Osaka, Japan) and cultured
as instructed by the supplier. Malignant cell lines and
HUVECs were cultured at 37°C under 5% carbon dioxide
and 95% air in 75 cm2 plastic tissue culture flasks. The
culture medium for all the malignant cell lines was sup-
plemented with 5% fetal calf serum (FCS). The medium for
human endothelial cells contained 2% fetal bovine serum,
10 ng ml-' epidermal growth factor and 1 mg ml- ' hydrocor-
tisone. When the cells were grown to subconfluence, they
were further incubated with 20 ml of fresh medium for 48 h,
and the spent media of these cell cultures were collected and
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analysed. To prepare cell samples for immunostaining, cells
were seeded into wells of chamber slides at an appropriate
cell population of about 1 x 105 cm-2 and cultured for 2-7
days under the same conditions until they had grown to
subconfluence.
Measurement of tumour markers in the spent media
Concentrations of three tumour markers (CAl9-9, CEA and
DUPAN-2) in the spent media were measured. Fresh
medium supplemented with 5% FCS was used as negative
control. The assay kits used for the detection of each antigen
were as follows: ELSA CIS CA19-9 test kit (CBI, Saclay,
France) for CA19-9, CEA RIABEAD kit (Dainabot, Tokyo,
Japan) for CEA and DUPAN-2 EIA kit (Kyowa Medix,
Tokyo, Japan) for DUPAN-2. For the DUPAN-2 EIA kit,
the inter- and intra-assay coefficients of variation (CVs) at a
concentration of 400 U ml1' were 5.01% (n = 5) and 2.65%
(n = 10) respectively. The limit of detectability of the three
kits was 10 U ml-', 0.5 ngml-' and 25 U ml-' respec-
tively.
Radioimmunoassayfor ET-J, ET-2 and ET-3
Extracton of the spent media and radioimmunoassay for
ET-1 was performed by the previously established method
(Kusuhara et al., 1990). The procedures for ET-2 and ET-3
will be reported elsewhere (M. Kusuhara et al., manuscript in
preparation). Briefly, the spent medium (20 ml) retained on
the ODS cartridge was eluted with 80% acetonitrile in 0.1%
trifluoroacetic acid, lyophilised and assayed. Fresh medium
supplemented with 5% FCS was used as negative control.
Synthetic ET-1, ET-2 or ET-3 conjugated to porcine thyro-
globulin was emulsified with an equal volume of complete
Freund's adjuvant and used for immunisation. Antisera
obtained from immunised guinea pigs were specific for each
ET isoform. In the ET-2 radioimmunoassay, the amount of
ET-2 which inhibited labelled antigen binding by 50% was
10 fmol per tube. The inter- and intra-assay CVs at 20 fmol
per tube were 8.0% (n = 8) and 5.0% (n = 10) respectively.
When the cross-reactivity of ET-2 was taken to be 100%, the
cross-reactivities of ET-1, big ET-1 and ET-3 were 0.003%,
0.008% and less than 0.002% respectively. For ET-3, the
amount of ET-3 that inhibited the labelled antigen binding
by 50% was 20 fmol per tube. The inter- and intra-assay CVs
at 20 fmol per tube were 7.7% (n = 8) and 5.5% (n = 10)
respectively. When the cross-reactivity of ET-3 was taken to
be 100%, the cross-reactivities of ET-1, big ET-1 and ET-2
were less than 0.005%. In the present experimental condi-
tions, the lowest detectable level of ET-1, ET-2 and ET-3 in
the spent media was 2.5 pM, 2.5 pM and 5.0 pM respectively.
The assay was performed in 0.1 M phosphate buffer pH 7.4,
containing 0.1 M sodium chloride, 0.06% (v/v) mono-
ethanolamine, 1% (w/v) disodium EDTA, 0.9% tetrasodium
EDTA and 0.1% BSA. The synthetic peptides for the ET
isoforms were used for the assay standards. After incubation
Table I Concentrations of CA19-9, CEA and DUPAN-2 in spent media of human pancreatic cancer cell lines
and HUVECs
CA19-9 CEA DUPAN-2
Cells (Umr-') (ngml-') (Umr-')
Pancreatic cancer
KPIN (moderately differentiated adenocarcinoma) <10 <0.5 <25
ASPC-1 (moderately well-differentiated adenocarcinoma) 39 <0.5 395
H48N (well-differentiated adenocarcinoma) 1,350 <0.5 <25
KP3 (adenosquamous carcinoma) 14 <0.5 <25
PANC-1 (undifferentiated carcinoma) <10 <0.5 <25
FA-6 (undifferentiated pleomorphic carcinoma) 427 0.8 <25
PSN-1 (poorly differentiated adenocarcinoma) <10 <0.5 <25
CAPAN-1 (adenocarcinoma) 85 47.0 36,800
BxPC-3 (moderately well-differentiated adenocarcinoma) 543 11.9 <25
CAPAN-2 (adenocarcinoma) 1,410 <0.5 115
KP2 (moderately differentiated adenocarcinoma) 26,400 3.0 <25
MIAPaCa-2 (undifferentiated carcinoma) <10 <0.5 <25
HUVEC <10 <0.5 <25
Control <10 <0.5 <25
Table II Concentrations of ET and TM in spent media or cell lysates of human pancreatic cancer cell lines and HUVECs
ET content TM content
ET-1 ET-2 ET-3 Cell lysate Spent media
Cells (pM) (pM) (pM) (ngml-'10-6 cells) (ngml')
Pancreatic cancer
KPIN (moderately differentiated adenocarcinoma) 110.0 <2.5 <5.0 1.4 <0.3
ASPC-1 (moderately well-differentiated adenocarcinoma) 81.0 <2.5 <5.0 65.0 20.0
H48N (well-differentiated adenocarcinoma) 57.0 <2.5 <5.0 150.0 4.4
KP3 (adenosquamous carcinoma) 53.0 <2.5 <5.0 70.0 2.5
PANC-1 (undifferentiated carcinoma) 44.0 <2.5 <5.0 0.31 <0.3
FA-6 (undifferentiated pleomorphic carcinoma) 37.0 <2.5 <5.0 0.60 <0.3
PSN-1 (poorly differentiated adenocarcinoma) 32.0 <2.5 <5.0 54.0 3.2
CAPAN-1 (adenocarcinoma) 16.0 <2.5 <5.0 0.70 0.50
BxPC-3 (moderately well-differentiated adenocarcinoma) 12.0 <2.5 <5.0 110.0 13.0
CAPAN-2 (adenocarcinoma) 6.3 8.0 <5.0 87.0 2.0
KP2 (moderately differentiated adenocarcinoma) 5.2 <2.5 <5.0 2.2 <0.3
MIAPaCa-2 (undifferentiated carcinoma) <2.5 <2.5 <5.0 <0.3 <0.3
HUVEC 410.0 <2.5 < 5.0 18.0 1.4
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for 24 h at 4°C, diluted goat anti-guinea pig gamma-globulin
antibody was added and further incubation was continued
for 24 h at 4°C. The bound antigen was separated from free
['251I]ET by centrifugation at 1,500g for 30 min. After the
supernatant was decanted, the precipitant was counted with a
gamma-counter.
detected with diaminobenzidine used as a chromogen.
Endogenous peroxidase was blocked with hydrogen peroxide
in methanol. All procedures were performed at room
temperature.
Results
Gelpermeation chromatography
Extracts prepared from the spent media of two pancreatic
cancer cell lines (KP1N and KP3) and HUVECs were
chromatographed by using a Sephadex G-50 superfine col-
umn by the previously reported method (Kusuhara et al.,
1990). The column was calibrated with ["5I]ET-l, [251I]BSA
and [1251]sodium iodide.
Detection oftumour markers in the spent media
The concentrations of the three tumour markers in the spent
media of the 12 pancreatic cancer cell lines are shown in
Table I. CA19-9 was detected in eight cell lines (67%). CEA
and DUPAN-2 were detectable in four (33%) and three
(25%) cell lines respectively.
Measurement ofthrombomodulin in cell lysate andspent media
Confluent monolayer or suspension cells grown in a 100 mm
culture dish were solubilised with a total of 2 ml of 0.5%
Triton X-100 in 2 mM phenylmethylsulphonyl fluoride,
0.15 M sodium chloride, 50 mM Tris-HCl, pH 7.5, for 1 h at
4°C. They were collected into 2 ml microfuge tubes, centri-
fuged and the TM content of the supernatant was measured
by enzyme immunoassay. The above-mentioned buffer was
used as a negative control. Spent media were prepared in the
same manner as described elsewhere in this paper. Fresh
medium supplemented with 5% FCS was used as a negative
control. Enzyme immunoassay for TM was performed by the
previously described method (Ishii et al., 1990) with minor
modifications. The detection limit was 0.3 ng ml-. The TM
content of the cell lysate was first evaluated as ng per ml of
lysate, then corrected according to the number of cells in the
culture dish and reported as ngml-' 10-6 cells.
Northern blot analysis
Four pancreatic cancer cell lines were examined for expres-
sion of TM mRNA. After total cellular RNA was extracted
by the acid guanidinium-phenol-chloroform method (Chom-
czynski & Sacchi, 1987), poly-A(+) RNA was selected with
Oligotex dT-30 (Kuribayashi et al., 1988). Gel electrophoresis
and Northern blot hybridisation were performed as reported
previously (Honda et al., 1988) with minor modification.
Briefly, 5pg of mRNA per lane was separated on a 1%
formaldehyde-agarose gel, and transferred to Hybond-N
(Amersham). Hybridisation was performed at 42°C for 20 h
in hybridisation buffer containing 50% formamide and 0.8 M
sodium chloride. Washing was performed three times with
2 x SSC containing 0.1% SDS at 50°C for 10min. For detect-
ing TM mRNA, an oligodeoxyribonucleotide was syn-
thesised and used as the probe. Its sequence was 5'-CAC
CGA GGA GCG CAC TGT CAT TAG GTG GCC CCG
CAG TCC GTC GCA GAT CTG ACT GGC ATT-3', which
is the anti-sense sequence for nucleotides 139-198 of TM
(Suzuki et al., 1987). It was labelled with [7y-32P]ATP and used
at a concentration of about 5 x 106 c.p.m. ml-'. P-Actin
mRNA running at about 2.0 kb was also examined to deter-
mine the integrity of these mRNA samples by the previously
described method (Honda et al., 1988).
Immunostaining procedurefor thrombomodulin
After cells grown in chamber slides were fixed with 10%
buffered formalin for 1 h, the slides were rinsed with
phosphate-buffered saline (PBS) containing 3% BSA for
30 min. TM was detected by the avidin-biotin-peroxidase
method by using a monoclonal antibody, TMMAb2O (Ishii et
al., 1990), as a primary antibody. The slides were incubated
with TMMAb20 at a concentration of 1 itg ml l in PBS
containing 3% BSA for 6 h, and washed in PBS. Then a
biotinylated anti-mouse IgG antibody was added as a second
antibody at the recommended concentration and the slides
were incubated with a solution of the avidin-biotinylated
horseradish peroxidase complex for 30 min. Peroxidase was
Endothelins in spent media
As shown in Table II, immunoreactive (IR) ET-1 was de-
tected in the spent media of 11 of the 12 pancreatic cancer
cell lines (92%). The concentrations of IR-ET-1 ranged from
5.2 to 110 pM. HUVECs also produced a large amount of
IR-ET-1, at a concentration of 410pM. On the other hand,
IR-ET-2 and IR-ET-3 were not detectable in any cell lines in
this study, except that IR-ET-2 was detected in one cell line
at a concentration of 8.0 pM. None of these three IR-ETs
were detectable in fresh medium supplemented with 5% FCS.
For malignant cells other than pancreatic cancer, there was
no IR-ET at detectable level in any of the four cell lines
examined (data not shown).
Gelfiltration studies
The gel filtration patterns of the extracts prepared from the
spent media of two pancreatic cancer cell lines and HUVECs
are shown in Figure 1. The major peak was eluted at the
position identical to that of synthetic ET-1.
Thrombomodulin in the cell lysates and in the spent media
The concentrations of TM in the cell lysate and in the spent
media are shown in Table II. Cell lysates prepared from 11
pancreatic cancer cell lines (92%) contained various amounts
of TM ranging from 0.31 to 150 ng ml- 10-6 cells. Further-
more, TM was also detected in the spent media of seven of
those 11 cell lines (58%), especially in the cell lines contain-
ing relatively large amounts of TM in cell lysates. Only one
cell line, MIAPaCa-2, which did not produce ET-1 either, did
not produce a detectable amount of TM in its cell lysate. On
the other hand, HUVECs expressed TM at a concentration
of 18 ngml-' 10-6 cells. TM was not detected in buffer con-
taining detergent and in fresh medium supplemented with
5% FCS. Of the other malignant cell types, A-549 cells
contained TM at a concentration of 0.45 ngml' 10-6 cells,
but TM was not detected in cell lysates of the other three cell
lines (data not shown).
Expression ofmRNAfor thrombomodulin
The autoradiogram ofNorthern blot analysis for TM mRNA
in four pancreatic cancer cell lines is shown in Figure 2. A
band with a molecular size of approximately 4.3 kb was
detected in the ASPC-1 and BxPC-3 cell lines, which pro-
duced large amounts of TM. In contrast, there was no band
in FA-6 and MIAPaCa-2, which produced only a small or
undetectable amount of TM. P-Actin mRNA was expressed
in all the cell lines tested.
Immunostainingfor thrombomodulin
Positive staining for TM was obtained in all 11 preparations
of pancreatic cancer cells (92%) whose lysates contained
amounts of TM detectable by enzyme immunoassay. Positive
staining was limited to the cell surface. In contrast, specific
staining was not detected in MIAPaCa-2 cells, in which TM1062 T. OIKAWA et al.
was not detectable in the cell lysate by enzyme immunoassay.
Typical examples of positive and negative staining cells are
shown in Figure 3.
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Figure 1 Gel filtration patterns of IR-ET-1 extracted from con-
ditioned media of pancreatic cancer cell lines and human
umbilical vein endothelial cells (HUVEC). a, HUVEC; b, KPIN;
c, KP3. Markers are shown at the top.
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Figure 2 Expression of TM mRNA in human pancreatic cancer
cell lines. a, ASPC-1; b, BxPC-3; c, FA-6; d, MIAPaCa-2. 28S
and 18S ribosomal RNA were used as molecular size
markers.
Figure 3 Cells stained by monoclonal antibody for thrombo-
modulin. a, ASPC-1; b, PSN-1; c, MIAPaCa-2 (original
magnification x 840).
Discussion
Twelve human pancreatic cancer cell lines were examined in
the present study. We analysed the production and the
release of three tumour markers in comparison to ET-1 and
TM. CA19-9 and DUPAN-2 are relatively specific for pan-
creatic cancer, while CEA is not specific but is frequently
produced by pancreatic cancer cells (Satake, 1991). In this
study, eight of the 12 cell lines were found to produce
CA19-9, and several produced CEA or DUPAN-2 as well.
The four remaining cell lines were characterised mainly by
morphological analysis (Lieber et al., 1975; Yunis et al.,
1977; Owens et al., 1979; Yamada et al., 1986; Ikeda et al.,
1990), which suggested that they originated from pancreatic
cancer.
Using these pancreatic cancer cell lines, we confirmed our
previous observation that ET-1 is frequently produced in
human pancreatic cancer cell lines (Kusuhara et al., 1990).
Further research revealed that the human genome has two
other DNA sequences similar to ET-1 (Inoue et al., 1989),
and these two putative peptides were termed ET-2 and ET-3.
Both are produced by several types of cells (Saida et al.,
1989; MacCumber et al., 1990), but not by endothelial cells.
With regard to ET-2 and ET-3, pancreatic cancer cells did
not produce either, except for a minute amount of ET-2 in
only one cell line. Based on these observations, it isENDOTHELIN AND THROMBOMODULIN IN PANCREATIC CANCER 1063
reasonable to postulate that the pattern of expression of ET
isoforms in human pancreatic cancer cell lines is similar to
that of endothelial cells, which suggests that most of the
pancreatic cancer cell lines share one of the properties of
vascular endothelial cells (Kusuhara et al., 1990): the produc-
tion of ET-1.
We extended our study to determine whether another pro-
duct of endothelial cells is produced by pancreatic cancer cell
lines. TM is a membrane-bound glycoprotein with the ability
to modulate blood coagulation (Esmon et al., 1982;
Maruyama et al., 1985), and it is dominantly expressed in
endothelial cells and the placenta. The following results
clearly demonstrate that human pancreatic cancer cells fre-
quently produce TM. First, TM was detected by specific
enzyme immunoassay in almost all pancreatic cancer cell
lysates and in the majority of the spent media. It is worth
noting that pancreatic cancer cells produce a considerable
amount of TM compared with that produced by human
umbilical vein endothelial cells. Second, TM was also
detected immunocytochemically in these cells. All of the cell
lines in which TM was detected by enzyme immunoassay
showed positive staining for TM. The distribution pattern of
TM was compatible with that in endothelial cells (Esmon et
al., 1982; Maruyama et al., 1985). Third, TM mRNA was
expressed in two pancreatic cancer cell lines producing a
large amount of TM. There are several studies on detection
of TM in human primary tumours of vascular endothelial
and syncytiotrophoblastic cell origin (Yonezawa et al., 1987,
1988), malignant pleural mesothelioma (Collins et al., 1992)
and lung cancer (Tamura et al., 1993). The fact that TM was
detected in almost all pancreatic cancer cell lines suggests
that TM could serve as a useful marker for primary human
pancreatic carcinoma. Recent research also revealed in-
creased plasma TM levels in pancreatic cancer patients
(Lindahl et al., 1993). Together with the possibility that it
reflects coagulopathy often seen in pancreatic cancer patients,
this phenomenon might be explained in part by the produc-
tion of TM in pancreatic cancer tissue. This subject merits
further investigation in the future.
The present study revealed that pancreatic cancer cells
possess the biological characteristic of producing two pro-
ducts of endothelial cells, ET-1 and TM. Both ET-1 and TM
were detected more frequently than tumour markers such as
CA19-9, CEA and DUPAN-2. There seems to be no appar-
ent correlation between ET-1 and/or TM production and the
degree of differentiation of the tumours from which the cell
lines were derived. Interestingly, placental syncytiotropho-
blasts, which abundantly express TM as was the case for
endothelial cells, do not produce ET-1 (Van Papendorp et al.,
1991). These facts raise the possibility that pancreatic cancer
cells share some properties of vascular endothelial cells,
rather than syncytiotrophoblasts. It might be that the patho-
logical nature of pancreatic cancer cell growth, such as
potent invasiveness (Furuta et al., 1992), has some relation-
ship to the mode of endothelial cell growth, which also seems
to invade adjacent tissues (Furcht, 1986). In this context, the
characteristics of pancreatic cancer cells presented here might
be useful in investigating the biology of pancreatic cancer in
the future.
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